Skip to main content

Table 1 Baseline characteristics and first-line treatment

From: Clinical outcomes of advanced non-small cell lung cancer patients harboring distinct subtypes of EGFR mutations and receiving first-line tyrosine kinase inhibitors: brain metastasis and de novo T790M matters

 

Uncommon (N = 74)

19del (N = 530)

L858R (N = 477)

p-value

Sex

   

0.38

 female

41(55.4%)

304(57.4%)

292(61.2%)

 

 male

33(44.6%)

226(42.6%)

185(38.8%)

 

Age, years

   

0.07

  ≤ 60

25(33.8%)

228(43.0%)

175(36.7%)

 

  > 60

49(66.2%)

302(57.0%)

302(60.4%)

 

KPS

   

0.11

 90-100

66(89.2%)

411(77.5%)

391(82.0%)

 

 70-89

7(9.5%)

102(19.2%)

71(14.9%)

 

  ≤ 70

1(1.4%)

17(3.2%)

15(3.1%)

 

Lung M

   

0.18

 no

31(41.9%)

233(44.0%)

235(49.3%)

 

 yes

43(58.1%)

297(56.0%)

242(50.7%)

 

Adrenal gland M

   

0.56

 no

72(97.3%)

503(94.9%)

450(94.3%)

 

 yes

2(2.7%)

27(5.1%)

27(5.7%)

 

Liver M

   

0.90

 no

68(91.9%)

494(93.2%)

445(93.3%)

 

 yes

6(8.1%)

36(6.8%)

32(6.7%)

 

Brain M

   

0.51

 no

51(68.9%)

382(72.1%)

355(74.4%)

 

 yes

23(31.1%)

148(27.9%)

122(25.6%)

 

Distant LN M

   

0.27

 no

41(55.4%)

259(48.9%)

255(53.5%)

 

 yes

33(44.6%)

271(51.1%)

222(46.5%)

 

Bone M

   

0.02

 no

51(68.9%)

298(56.2%)

248(52.0%)

 

 yes

23(31.1%)

232(43.8%)

229(48.0%)

 

Oligo-M

   

0.43

 no

64(86.5%)

445(84.0%)

389(81.6%)

 

 yes

10(13.7%)

84(16.0%)

88(18.4%)

 

TKI generations

   

< 0.001

 1st

45(60.8%)

476(89.8%)

409(85.7%)

 

 2nd

16(21.6%)

20(3.8%)

16(3.4%)

 

 3rd

13(17.6%)

34(6.4%)

52(10.9%)

 
  1. Abbreviation: M metastasis, LN lymph node